EP1643959A4 - Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment - Google Patents

Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment

Info

Publication number
EP1643959A4
EP1643959A4 EP04753588A EP04753588A EP1643959A4 EP 1643959 A4 EP1643959 A4 EP 1643959A4 EP 04753588 A EP04753588 A EP 04753588A EP 04753588 A EP04753588 A EP 04753588A EP 1643959 A4 EP1643959 A4 EP 1643959A4
Authority
EP
European Patent Office
Prior art keywords
mixtures
methods
pain treatment
oligomer conjugates
calcitonin drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04753588A
Other languages
German (de)
French (fr)
Other versions
EP1643959A2 (en
Inventor
Gordana Kosutic
Nnochiri N Ekwuribe
Christopher H Price
Aslam M Ansari
Amy L Odenbaugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of EP1643959A2 publication Critical patent/EP1643959A2/en
Publication of EP1643959A4 publication Critical patent/EP1643959A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP04753588A 2003-06-24 2004-05-27 Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment Withdrawn EP1643959A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48213003P 2003-06-24 2003-06-24
PCT/US2004/016784 WO2005004792A2 (en) 2003-06-24 2004-05-27 Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment

Publications (2)

Publication Number Publication Date
EP1643959A2 EP1643959A2 (en) 2006-04-12
EP1643959A4 true EP1643959A4 (en) 2010-06-09

Family

ID=34061937

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04753588A Withdrawn EP1643959A4 (en) 2003-06-24 2004-05-27 Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment

Country Status (3)

Country Link
EP (1) EP1643959A4 (en)
JP (1) JP4829783B2 (en)
WO (1) WO2005004792A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308263B2 (en) 2011-10-21 2016-04-12 Seachaid Pharmaceuticals, Inc. Pharmaceutical compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098451A1 (en) * 2001-06-04 2002-12-12 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
KR100345214B1 (en) * 1999-08-17 2002-07-25 이강춘 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098451A1 (en) * 2001-06-04 2002-12-12 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTONIO QUATRARO ET AL: "CALCITONIN IN PAINFUL DIABETIC NEUROPATHY", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 339, no. 8795, 1 March 1992 (1992-03-01), pages 746 - 747, XP008073556, ISSN: 0140-6736 *
See also references of WO2005004792A2 *
SIMANSKI C ET AL: "[Therapy of phantom pain with salmon calcitonin and effect on postoperative patient satisfaction]", DER CHIRURG; ZEITSCHRIFT FÜR ALLE GEBIETE DER OPERATIVEN MEDIZEN JUN 1999 LNKD- PUBMED:10427454, vol. 70, no. 6, June 1999 (1999-06-01), pages 674 - 681, XP002578700, ISSN: 0009-4722 *

Also Published As

Publication number Publication date
JP2007521268A (en) 2007-08-02
EP1643959A2 (en) 2006-04-12
WO2005004792A3 (en) 2005-09-01
JP4829783B2 (en) 2011-12-07
WO2005004792A2 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
IL172316A0 (en) Novel compounds and their use in therapy
GB2414670B (en) Homeopathic formulations useful for treating pain and/or inflammation
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
AU2003293376A8 (en) Anti-angiogenic compounds and their use in cancer treatment
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
HK1162948A1 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer (hemiasterlin)
EP1809603A4 (en) Nitrobenzindoles and their use in cancer therapy
AU2003298794A8 (en) Recombinant immunotoxin and use in treating tumors
GB0212405D0 (en) Composition and its therapeutic use
SG110107A1 (en) Compound and use in treatment
AU2003250831A8 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
EP1666046A4 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
EP1643959A4 (en) Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment
GB0128431D0 (en) Improvements in and relating to portable defibrillators
EP1583543A4 (en) Methods and therapeutic compositions in the treatment of advanced cancer
AU2003209459A8 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
IL174968A0 (en) The use of ifenprodil in the treatment of pain
GB0225688D0 (en) Therapeutic compounds and their use in therapy
GB0325598D0 (en) Compound and use in treatment
GB0203043D0 (en) Benzimidazloe compounds their preparation and their use in therapy
GB0203042D0 (en) Anthraquinine compounds their preparation and their use in therapy
GB0130733D0 (en) Therapeutic compounds and their use in therapy
GB0313065D0 (en) Vaccine and therapeutic treatment
GB0301298D0 (en) Therapy device and methods of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060123

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20060227BHEP

Ipc: C07K 7/00 20060101ALI20060227BHEP

Ipc: C07K 14/535 20060101ALI20060227BHEP

Ipc: C07K 1/113 20060101AFI20060227BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOCON LIMITED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ODENBAUGH, AMY, L.

Inventor name: ANSARI, ASLAM, M.

Inventor name: PRICE, CHRISTOPHER, H.

Inventor name: EKWURIBE, NNOCHIRI, N.

Inventor name: KOSUTIC, GORDANA

A4 Supplementary search report drawn up and despatched

Effective date: 20100512

17Q First examination report despatched

Effective date: 20101001

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151201